.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Federal Trade Commission
Fuji
Medtronic
Colorcon
Farmers Insurance
Chubb
Accenture
Fish and Richardson
Cantor Fitzgerald

Generated: December 15, 2017

DrugPatentWatch Database Preview

BRIDION Drug Profile

« Back to Dashboard

Which patents cover Bridion, and when can generic versions of Bridion launch?

Bridion is a drug marketed by Organon Sub Merck and is included in one NDA. There are three patents protecting this drug.

This drug has fifty-four patent family members in twenty-nine countries and eleven supplementary protection certificates in ten countries.

The generic ingredient in BRIDION is sugammadex sodium. One supplier is listed for this compound. Additional details are available on the sugammadex sodium profile page.

Summary for BRIDION

Drug patent expirations by year for BRIDION

Pharmacology for BRIDION

Ingredient-typegamma-Cyclodextrins

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Organon Sub MerckBRIDIONsugammadex sodiumSOLUTION;INTRAVENOUS022225-002Dec 15, 2015RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Organon Sub MerckBRIDIONsugammadex sodiumSOLUTION;INTRAVENOUS022225-001Dec 15, 2015RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Organon Sub MerckBRIDIONsugammadex sodiumSOLUTION;INTRAVENOUS022225-002Dec 15, 2015RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Organon Sub MerckBRIDIONsugammadex sodiumSOLUTION;INTRAVENOUS022225-001Dec 15, 2015RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Organon Sub MerckBRIDIONsugammadex sodiumSOLUTION;INTRAVENOUS022225-002Dec 15, 2015RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Organon Sub MerckBRIDIONsugammadex sodiumSOLUTION;INTRAVENOUS022225-002Dec 15, 2015RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Organon Sub MerckBRIDIONsugammadex sodiumSOLUTION;INTRAVENOUS022225-001Dec 15, 2015RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Organon Sub MerckBRIDIONsugammadex sodiumSOLUTION;INTRAVENOUS022225-001Dec 15, 2015RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: BRIDION

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,670,340 6-Mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: BRIDION

Country Document Number Estimated Expiration
Japan2003507335► Subscribe
European Patent Office1210090► Subscribe
Czech Republic298206► Subscribe
Colombia5251450► Subscribe
South Africa200203538► Subscribe
Israel149423► Subscribe
Poland356097► Subscribe
China1370073► Subscribe
Japan4782334► Subscribe
Argentina026605► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: BRIDION

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2008000068Germany► SubscribePRODUCT NAME: SUGAMMADEX ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725
0Finland► Subscribe
501Luxembourg► Subscribe91501, EXPIRES: 20230725
47/2008Austria► SubscribePRODUCT NAME: SUGAMMADEX; 6-PER-DEOXY-6-PER-(2-CARBOXYETHYL) THIO-Y-CYCLODEXTRIN UND PHARMAZEUTISCH VERTR√ĄGLICHES SALZ HIERVON
C/GB08/057United Kingdom► SubscribePRODUCT NAME: SUGAMMADEX; REGISTERED: UK EU/1/08/466/001 20080725; UK EU/1/08/466/002 20080725
0356Netherlands► Subscribe
C0052France► SubscribePRODUCT NAME: SUGAMMADEX SODIUM; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725
1259550/01Switzerland► SubscribeFUSION; FORMER OWNER: ORGANON BIO SCIENCES NEDERLAND B.V., NL
/2008Austria► SubscribePRODUCT NAME: SUGAMMADEX; 6-PER-DEOXY-6-PER-(2-CARBOXYETHYL) THIO-Y-CYCLODEXTRIN UND PHARMAZEUTISCH VERTRAEGLICHES SALZ HIERVON; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725
2009 00002Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Queensland Health
Dow
Deloitte
Cipla
Fish and Richardson
Medtronic
Fuji
Chinese Patent Office
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot